CRISPR
Resources
Learn more about Myllia’s proof-of-concept single-cell CRISPR screens incl. biotechnology resources, posters, slide decks, and videos
General resources
Non-confidential introduction – Myllia
At Myllia, we use the CROP-Seq technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution.
Myllia Launches the VISTA Platform Enabling Target Discovery in Primary Human Myeloid Cells
Myllia's breakthrough VISTA™ platform opens new frontiers in drug target discovery enabling genome-wide CRISPR screens in primary human Macrophages and Dendritic Cells
Our Factsheet
Check out Myllia's technology platform enabling drug target discovery and functional genomics at single-cell resolution
CRISPR-ready cancer cell lines for CRISPRn & CRISPRi screens
Browse through our catalogue of CRISPR-ready cancer cell lines for your next tailor-made CRISPR screens
CRISPR screens in primary human cells for target identification and validation
Myllia performs large-scale CRISPR screens in primary human cells to identify drug targets using functional genomics. Our approach captures primary human cell biology and thus increases the chance of success for your next drug discovery campaign.
CROP-Seq training datasets for AI-based foundation models of human cell biology
A foundation model of the human cell is a digital representation of the biology of a human cell. The amount of publicly available training data for such models is very limited, and Myllia's CROP-Seq perturbation datasets are a powerful source of information to fuel AI/ML-based engines accelerating drug target discovery.
Next-generation CRISPR screening for drug target discovery
De-risk target discovery and drug development using the best possible validated targets
CRISPR screens for immuno-oncology (IO) research
CROP-Seq (Perturb-Seq) in primary T cells - Utilize our tailor-made CRISPR screens to characterize your immuno-oncology drug candidates and CAR-T cell products
RESEARCH ARTICLE in Cell Reports, May 2024
Together with Boehringer Ingelheim, Myllia performed a CROP-Seq screen contributing to the publication: "Genetic dependencies associated with transcription factor activities in human cancer cell lines" in Cell Reports, May 2024
Posters
Poster | Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing
T helper 2 (Th2) cell differentiation plays a critical role in regulating allergic responses, defense against parasites, and immune homeostasis. In a CROP-Seq experiment with CD4+ T cells, Th2-skewed cells were studied using a sgRNA library targeting 102 genes with a targeted read-out of 300 mRNAs.
Poster | Myllia’s VISTA platform for unbiased target discovery in primary human DCs and macrophages
With a focus on immune cells, Myllia’s VISTA™ platform enables the discovery of high-value drug targets and deep insights into immune cell function, including primary human dendritic cells (DCs) and macrophages.
Poster | Design of sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
Slide decks
Large-scale CROP-Seq perturbation datasets available for licensing at Myllia Biotechnology
Myllia provides scalable, single-cell perturbation datasets that can fuel AI-driven foundation models of human biology - check out five CROP-Seq datasets available off-the-shelf
Design of highly efficient sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
Videos
Video | About us
Discover the unique CRISPR screening portfolio developed at Myllia Biotechnology
Video | How do CRISPR screens work?
Explore how we can use CRISPR screens to support drug target identification
Video | CRISPR/Cas9-based screens: CRISPRko vs. CRISPRi
Learn more about the differences of CRISPR/Cas9-based CRISPRko (knockout) and CRISPRi (interference) screens
Video | CROP-Seq: Single-cell CRISPR screening
Learn how the CROP-Seq (Perturb-Seq) technology at Myllia can help to elucidate novel drug targets at single-cell resolution
Video | Targeted sequencing
Would you like to know more about targeted sequencing applications? Explore how tailored PCR panels can boost the NGS read-outs of your next CRISPR screens
Video | Primary human T cell CRISPR screening
At Myllia, CRISPR screens are performed in primary human T cells to explore factors of T cell activation, differentiation and exhaustion. Learn more about our CROP-seq technology to boost CAR-T and TCR-T cell potency!